594022 Disclosed herein is a solid pharmaceutical dosage form comprising linagliptin as a first active ingredient in an amount of 5 mg, 1-chloro-4-(?-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene as a second active ingredient in an amount from 5 mg to 25 mg, and one or more excipients； and the use of said dosage in the treatment of diabetes. Additionally, wherein the first active ingredient has a particle size distribution of X90<；200 µm, and the second active ingredient has a particle size distribution of 1 µm<；X90<；200 µm.
